Reaction

Hepatic Neoplasm reporting signals

Last recalculated 2026-09-14T18:28:35.993900+00:00 · 3,219 reports · 79 co-occurring drugs

As of the last recalculation, Hepatic Neoplasm appears in 3,219 FAERS reports alongside 79 co-occurring drug terms. The strongest observed disproportionality signal is OCTREOTIDE ACETATE (PRR 76.7).

Important: FAERS is a spontaneous, voluntary, unverified reporting system. PRR and ROR identify reporting patterns for investigation; they are not incidence rates and do not establish causation.

Drug	Co-reports	PRR	ROR
Octreotide Acetate	327	76.7	77.5
Lanreotide Acetate	68	57.3	57.8
Quinapril Hydrochloride	44	36.5	36.7
Glyburide	52	14.1	14.1
Imatinib Mesylate	58	13.7	13.7
Everolimus	103	13.5	13.5
Entecavir	23	12.8	12.8
Sorafenib	37	11.6	11.7
Linagliptin	30	10.7	10.7
Niraparib	36	10.6	10.6
Loperamide Hydrochloride And Dimethicone	50	10.2	10.2
Panitumumab	24	10.0	10.0
Sofosbuvir	30	9.9	9.9
Ribociclib	44	9.1	9.1
Rosuvastatin Calcium	38	8.8	8.8
Ado-Trastuzumab Emtansine	11	8.5	8.5
Fulvestrant	42	8.3	8.3
Thiotepa	12	8.2	8.2
Loperamide Hydrochloride	54	7.9	7.9
Regorafenib	14	7.8	7.8
Lapatinib	18	7.5	7.5
Terazosin Hydrochloride	10	7.3	7.3
Pancrelipase	41	6.9	7.0
Rifaximin	22	6.8	6.8
Capecitabine	94	6.8	6.8
Ciclesonide	13	6.2	6.2
Ribavirin	58	5.9	5.9
Drospirenone And Ethinyl Estradiol	38	5.6	5.6
Goserelin	11	5.3	5.3
Tenofovir Disoproxil Fumarate Tablets	7	5.3	5.3
Atezolizumab	31	5.2	5.2
Alpelisib	7	5.2	5.2
Imatinib	14	5.2	5.2
Rucaparib	7	5.1	5.1
Lactulose	30	5.1	5.1
Basiliximab	9	5.0	5.0
Trifluridine And Tipiracil	8	4.8	4.8
Insulin	41	4.8	4.8
Pazopanib Hydrochloride	20	4.8	4.8
Everolimus Tablets	12	4.6	4.6
Exemestane	15	4.5	4.5
Irinotecan Hydrochloride	9	4.5	4.5
Insulin Glargine-Yfgn	15	4.5	4.5
Labetalol	9	4.4	4.4
Letrozole	41	4.3	4.3
Trastuzumab	45	4.3	4.3
Olaparib	13	4.0	4.0
Pertuzumab	16	3.8	3.8
Avapritinib	7	3.7	3.7
Ledipasvir And Sofosbuvir	11	3.7	3.7
Letrozole Tablets	27	3.7	3.7
Bevacizumab	68	3.6	3.6
Gefitinib	5	3.6	3.6
Glecaprevir And Pibrentasvir	6	3.5	3.5
Prochlorperazine Maleate	5	3.5	3.5
Trametinib	13	3.5	3.5
Dabrafenib	11	3.4	3.4
Sunitinib Malate	20	3.3	3.3
Bleomycin Sulfate	5	3.1	3.1
Peginterferon Alfa-2A	26	3.1	3.1
Velpatasvir And Sofosbuvir	6	3.0	3.0
Gemcitabine Hydrochloride	22	2.7	2.7
Deferasirox	11	2.7	2.7
Gemcitabine	16	2.6	2.6
Paclitaxel	39	2.6	2.6
Bosentan	19	2.4	2.4
Tenofovir Disoproxil Fumarate	12	2.4	2.4
Osimertinib	11	2.2	2.2
Vemurafenib	4	2.2	2.2
Temozolomide	7	2.2	2.2
Palbociclib	30	2.0	2.0
Cabozantinib	15	2.0	2.0
Paliperidone Palmitate	10	2.0	2.0
Encorafenib	3	2.0	2.0
Abemaciclib	6	1.9	1.9
Ravulizumab	4	1.9	1.9
Durvalumab	5	1.6	1.6
Palivizumab	3	1.3	1.3
Somatropin	14	1.2	1.2

Related reactions

Data source: openFDA FAERS. See the OpenPV methodology and limitations.